Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients
Acta Neurologica Scandinavica2014Vol. 130(1), pp. 46–52
Citations Over TimeTop 15% of 2014 papers
Sandra Nischwitz, Hans von Faber, Philipp G. Sämann, Helena S. Domingues, Gurumoorthy Krishnamoorthy, Matthias Knop, Felix Müller‐Sarnowski, Alexander Yassouridis, Frank Weber
Abstract
Reduction in increased IL-16 levels may be of relevance for the therapeutic effect of IFN-β1a in MS. Easily accessible IL-16 serum levels hold a potential as biomarker of treatment efficacy in MS.
Related Papers
- → Beneficial Effect of Tolerogenic Dendritic Cells Pulsed with MOG Autoantigen in Experimental Autoimmune Encephalomyelitis(2014)86 cited
- → Cutting Edge: C3, a Key Component of Complement Activation, Is Not Required for the Development of Myelin Oligodendrocyte Glycoprotein Peptide-Induced Experimental Autoimmune Encephalomyelitis in Mice(2001)88 cited
- → MYMD-1, a novel alkaloid compound, ameliorates the course of experimental autoimmune encephalomyelitis(2019)6 cited
- → Dependency of Experimental Autoimmune Encephalomyelitis Induction on MOG35–55 Properties Modulating Matrix Metalloproteinase-9 and Interleukin-6(2015)2 cited
- → Modeling Multiple Sclerosis in the Two Sexes: MOG<sub>35-55</sub>-Induced Experimental Autoimmune Encephalomyelitis(2023)